Comments Regarding Quantitative Labeling of Sodium, Potassium, and Phosphorus for OTC and Prescription Drug Products Share page: Docket Number: FDA-2021-D-0528 Download Document Issues: OTC Medicines Other Issues Labeling Quality Related Posts Comments Comments Regarding FDA Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products May 13, 2024 Press Releases and Statements CHPA Applauds Vermont for Passing Sun Safety Bill Empowering Students to Better Protect their Skin May 8, 2024 Press Releases and Statements Tennessee Expands Access to OTC Cold & Allergy Medications Containing PSE May 7, 2024